Histology-agnostic drug development — considering issues beyond the tissue

Nature Reviews Clinical Oncology, Published online: 11 June 2020; doi:10.1038/s41571-020-0384-0Therapies are being developed to treat cancers on the basis of specific molecular alterations and markers of immune phenotypes that transcend specific tumour histologies. The authors summarize the development and testing of approved histology-agnostic therapeutic agents, present data on other agents under development and discuss the challenges intrinsic to histology-agnostic drug development in oncology, including biological, regulatory, design and statistical considerations.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research